Research
Lactobacillus reuteri DSM 17938 (BioGaia)
10 peer-reviewed studies curated from PubMed and Semantic Scholar.
Studies
Sorted by quality and recency
Use of probiotics in the treatment of functional abdominal pain in children-systematic review and meta-analysis.
Systematic review and meta-analysis of 9 RCTs evaluating probiotic interventions for pediatric functional abdominal pain. Lactobacillus reuteri DSM 17938 was found to significantly reduce pain intensity and increase days without pain in children.
The effects of a 6-week intervention with Limosilactobacillus reuteri ATCC PTA 6475 alone and in combination with L. reuteri DSM 17938 on gut barrier function, immune markers, and symptoms in patients with IBS-D-An exploratory RCT.
This exploratory RCT investigated the effects of a 6-week intervention with Limosilactobacillus reuteri strains on gut barrier function, immune markers, and symptoms in IBS-D patients. The probiotic interventions did not significantly affect gut barrier function, but showed potential anti-inflammatory effects and symptom improvement, particularly in the dual strain group.
Effectiveness of Probiotics in Children With Functional Abdominal Pain Disorders and Functional Constipation: A Systematic Review.
Systematic review of RCTs investigating probiotics in children with functional abdominal pain disorders and functional constipation. Some evidence supports Lactobacillus rhamnosus GG in reducing abdominal pain in children with irritable bowel syndrome, but insufficient evidence exists for other probiotics or conditions.
Lactobacillus reuteri DSM 17938 in the prevention of antibiotic-associated diarrhoea in children: protocol of a randomised controlled trial.
This is a protocol for a double-blind, randomised, placebo-controlled trial assessing the effects of Lactobacillus reuteri DSM 17938 on the prevention of antibiotic-associated diarrhoea in children. The trial will enroll 250 children under 18 years receiving antibiotics, with the primary outcome being the frequency of diarrhoea and antibiotic-associated diarrhoea.
Limosilactobacillus reuteri DSM-17938 for preventing cough in adults with mild allergic asthma: A double-blind randomized placebo-controlled cross-over study.
A double-blind, randomized, placebo-controlled cross-over study investigated the effects of Limosilactobacillus reuteri DSM-17938 on capsaicin-evoked coughs in mild allergic asthmatics. The study found no significant difference in cough response, airway inflammation, or T-cell responses between the probiotic and placebo groups.
Lactobacillus reuteri DSM 17938 is effective in the treatment of functional abdominal pain in children: Results of the double-blind randomized study.
This randomized double-blinded controlled trial assessed the effect of Lactobacillus reuteri DSM 17938 on functional abdominal pain in children over 12 weeks, with a follow-up of 4 weeks. The study included 46 children and found that the intervention group experienced less severe abdominal pain and a significant increase in pain-free days. Pooled data from both parts of the study included 101 children, showing a significant increase in pain-free days in the L. reuteri group.
Randomised double blind placebo controlled trial on Lactobacillus reuteri DSM 17938: improvement in symptoms and bowel habit in functional constipation.
RCT of 56 patients with functional constipation comparing Lactobacillus reuteri DSM 17938 to placebo over 105 days. The probiotic significantly improved symptoms related to gas content, dysbiosis, and defecation, but not stool consistency.
Lactobacillus reuteri DSM 17938 in the Treatment of Functional Abdominal Pain in Children: RCT Study.
RCT investigating the effect of Lactobacillus reuteri DSM 17938 on functional abdominal pain and IBS in children. The intervention group had significantly more days without pain and reduced pain severity compared to placebo, though no difference in pain duration, stool type, or school absence.
Role of Lactobacillus reuteri DSM 17938 on Crying Time Reduction in Infantile Colic and Its Impact on Maternal Depression: A Real-Life Clinic-Based Study
This observational study evaluated the role of Lactobacillus reuteri DSM 17938 in reducing crying time in colicky infants in India. Supplementation resulted in a significant reduction of crying time and unexplained fussiness, with 85% of subjects showing a 50% reduction in crying time. Maternal depression scores also significantly decreased.
Safety and tolerability of Lactobacillus reuteri DSM 17938 and effects on biomarkers in healthy adults: results from a randomized masked trial.
This randomized, double-blind placebo-controlled trial investigated the safety and immune effects of Lactobacillus reuteri DSM 17938 in 40 healthy adults over 2 months. The probiotic was found to be safe and well-tolerated, with no significant changes in immunologic markers, but a small increase in fecal calprotectin was observed.